As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Foreign investors have significantly reduced holdings in many Nifty companies since September 2024. This has impacted top blue-chip stocks,...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...

Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...

Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...

Cipla's incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presenc...

Cipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under ...

In an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening it...

Sun Pharmaceutical, India's largest drugmaker by revenue, plans to launch its experimental anti-obesity and type 2 diabetes drug Utreglutid...

South African Health Products Regulatory Authority (SAHPRA) has approved the sweet-tasting, heat-stable and '4-in-1' fixed-dose combination...

Cipla reported an FCF of around Rs 3,400 crore in 2019-20 and is expected to report bigger numbers in the coming years due to increased gro...

Acquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.

Morgan Stanley and CLSA downgraded their ratings on Cipla after the drug maker reported a slower-than-expected rise in October-December net...